No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

Target·Modality

Indication

Stage

Deal Value

(USD Mn)

1

4/10

OncoX BioPharma

ABVC BioPharma

Small molecule

(BK-501,BK-502)

Controlled release formulation of each drug

혈전증,

제2형 당뇨병

inactive

105

2

4/16

Takeda 

Pharmaceutica

Kumquat 

Biosciences

Small molecule

(oral route, unclarified)

n/d

암

Preclinical

1,330

3

4/22

Ipsen SA

Skyhawk 

Therapeutics

Small molecule

(2 candidates, unclarified)

n/d

희귀 신경질환

Discovery

1,800

4

4/25

Ono Pharmaceutical

PRISM BioLab

Small molecule

(unclarified)

Protein-Protein interaction inhibitor

암

Discovery

n/d

5

4/25

Biolojic Design

Nektar 

Therapeutics

Monoclonal antibody

(NKTR-0165)

Tumor necrosis factor receptor 2 (TNFR2)

다발성 경화증,

자가면역질환

Preclinical

n/d

No.

Date

Acquires

Issuer

주요 파이프라인

금액 
(USD Mn)

1

4/3

Genmab AS

ProfoundBio US

-(PRO-1184) ADC, target : Topoisomerase1, FOLR1 / Solid tumors (임상 2상) 

-(PRO-1160) ADC, target : CD70 / Solid tumors (임상 2상)

-(PRO-1107) ADC, target : PTK7 / Solid tumors (임상 2상)

1,800

2

4/5

Merck & Co

Abceutics

-ADC “payload-binding selectivity enhancers” 플랫폼

208

3

4/10

Vertex 

Pharmaceuticals

Alpine Immune 

Sciences

-(acazicolcept) A fusion protein by vIgD플랫폼, target : ICOS, CD28 / autoimmune disease (임상 2상)

-(povetacicept) engineered B-cell modulator, target :BAFF, APRIL / IgA nephropathy (임상 2상)

4,900

4

4/11

Century 

Therapeutics

Clade 

Therapeutics

-(Cell therapy) iPSC immune cloaking and differentiation 플랫폼 / unspecified cancers (Preclinical)

35

5

4/23

Incyte Corp

Escient

Pharmaceuticals

-(EP-262) target : MRGPRX2 / autoimmune disease (임상 2상) 

-(EP-547) target : MRGPRX4 / Cholestaticpruritus, hepatitis B and hepatitis C (임상 2상)

750

6

4/25

Esteve

Pharmaceuticals

Hra Pharma Rare

Diseases

-(Zona Pellucida) 암백신 / ZP3 positive cancers (Preclinical)

294.12

7

4/29

Ono

Pharmaceutical

Deciphera

Pharmaceuticals

-(ripretinib; Qinlock) fourth-line gastrointestinal stromal tumor (GIST) (승인)

-(Vimseltinib; DCC-3014) target : CSF1R(FMS kinase) / advanced malignancy, AML 외 (임상 3상)

-(DCC-3116) target : ULK1/2 / RAS and RAF mutant advanced or metastatic solid tumors (임상 2상)

2,400